Cart is empty Researchers at Vanderbilt-Ingram Cancer Center have discovered a drug target on natural killer cells that could potentially trigger a therapeutic response in patients with immunotherapy-resistant, triple-negative breast cancer.
Researchers at Vanderbilt-Ingram Cancer Center have discovered a drug target on natural killer cells that could potentially trigger a therapeutic response in patients with immunotherapy-resistant, triple-negative breast cancer.
Leave A Comment